First time available for research use

TNF-α antibody

Adalimumab antibody from Humira®

Therapeutic TNF-α-antibody from the original Humira® commercial drug targeting the TNF-α-antigen, also referred to as Humira® or adalimumab antibody. Research-relevant quantities are available as licence-free consumable in aliquoted or diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.

Choose your antibody
Easy Access

Easy Access

Easy to order as license-free research consumable
Multiple batches

Multiple batches

Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs

Reduce costs

Up to 80% less compared to the original pharmaceutical price
Prompt delivery

Prompt delivery

Shipment within days worldwide according to GDP-standards
Documented origin

Documented origin

Information on batch, registration number, expiry date, GDP-compliant pedigree

What our clients say

Adalimumab / Humira

Product Reference

Drug nameHumira®
INNAdalimumab
API typeAdalimumab is a recombinant human monoclonal antibody expressed in Chinese Hamster Ovary cells.
Pharmacotherapeutic group
Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors.
ATC code
L04AB04
Target of antibody
TNF-α; Synonyms: DIF, TNF-alpha, TNFA, TNFSF2, RATTNF, Tnfa, tnf, TNF-a, TNFalpha, Tnfsf1a, TNFa, cTNF, Tnf-alpha, tnfa-like, TNF-ALPHA, dif, tnfa, xtnf, tnfsf2, tnf-alpha, Cachectin
General functionAdalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its
interaction with the p55 and p75 cell surface TNF receptors.
Adalimumab also modulates biological responses that are induced or regulated by TNF, including
changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1,
and ICAM-1 with an IC50 of0.1-0.2 nM).
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors.
Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of0.1-0.2 nM).
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after Humira administration. Patients treated with Humira usually experienced improvement in haematological signs of chronic inflammation.
A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In patients with Crohn’s disease, a reduction of the number of cells expressing inflammatory markers in the colon including a significant reduction of expression of TNFα was seen. Endoscopic studies in intestinal mucosa have shown evidence of mucosal healing in adalimumab treated patients.
Original license holder
Marketing authorisation numbers
EU/1/03/256/001 - 015
Marketing authorisation holder
AbbVie Ltd
Maidenhead
SL6 4UB
United Kingdom
Name of the manufacturer of the biological active substance
Name and address of the manufacturer(s) responsible for batch release
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
Mannitol
Citric acid monohydrate
Sodium citrate
Sodium dihydrogen phosphate dihydrate
Disodium phosphate dihydrate
Sodium chloride
Polysorbate 80
Sodium hydroxide
Water for injections